Dengue virus (DENV) is the cause of dengue fever.It is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus. Five serotypes of the virus have been found, all of which can cause the full spectrum of disease.
Based on the analysis of the envelope protein, at least...
Until a few hundred years ago, dengue virus was transmitted...
The DENV genome is about 11000 bases of positive-sense,...
Dengue fever virus (DENV) is an RNA virus of the family Flaviviridae; genus Flavivirus.Other members of the same genus include yellow fever virus, West Nile virus, Zika virus, St. Louis encephalitis virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kyasanur forest disease virus, and Omsk hemorrhagic fever virus.
- Society and culture
- In development
Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may increase the risk of severe dengue in those who have not previously been infected. It is given as three injections ov
CYD-TDV, sold under the brand name Dengvaxia and made by Sanofi Pasteur, is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology by replacing the PrM and E structural genes of the yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes. Evidence indicates that CYD-TDV is partially effective in preventing infection, but may lead to a higher risk of severe disease in those who have not been previously infected and then do go on to contra
In Indonesia it costs about US$207 for the recommended three doses as of 2016.
The 2017 dengue vaccine controversy in the Philippines involved a vaccination program run by the Philippines Department of Health. It vaccinated schoolchildren with Sanofi Pasteur's CYD-TDV dengue vaccine. Some of the children who received the vaccine had never been infected by t
DENVax or TAK-003 is a recombinant chimeric vaccine with DENV1, DENV3, and DENV4 components on a dengue virus type 2 backbone originally developed at Mahidol University in Bangkok and now funded by Inviragen and Takeda. Phase I and II trials were conducted in the United States, C
TV-003/005 is a tetravalent admixture of monovalent vaccines, that was developed by NIAID, that were tested separately for safety and immunogenicity. The vaccine passed Phase I trials and Phase II studies in US, Thailand, Bangaldesh, India and Brazil. NIH has conducted Phase I an
TDENV PIV is undergoing phase I trials as part of a collaboration between GlaxoSmithKline and the Walter Reed Army Institute of Research. A synergistic formulation with another live attenuated candidate vaccine is also being evaluated in a phase II study. In prime-boosting, one t
In December 2018, Dengvaxia was approved in the European Union. In May 2019, Dengvaxia was approved in the United States as the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes in people ages nine through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas. Dengue is endemic in the U.S. territories of American Samoa, Guam, Puerto Rico and the U.S. Virgin Islands. The safety and effectiveness of the vaccine was d
Dengue fever is caused by infection through viruses of the family Flaviviridae. The illness is most commonly transmitted by Aedes aegypti mosquitoes in tropical and subtropical regions.  Dengue virus has four different serotypes, each of which are antigenically related but have limited cross-immunity to reinfection.
Dengue virus is spread mostly by mosquitoes from the Aedes genus, especially the Aedes aegypti species of mosquito. Aides aegypti is the most likely type of mosquito to spread dengue, because it likes to live close to humans and feed off of people instead of animals. A person can get the dengue virus from just one mosquito bite.
Epidemic dengue has become more common since the 1980s. By the late 1990s, dengue was the most important mosquito-borne disease affecting humans after malaria, with around 40 million cases of dengue fever and several hundred thousand cases of dengue hemorrhagic fever each year. Significant outbreaks of dengue fever tend to occur every five or ...
People also ask
What does dengue virus mean?
Is West Nile virus the same as dengue?
What is the structure of yellow fever?
What is the scientific name of dengue virus?
- Risk Factors
Dengue (DENG-gey) fever is a mosquito-borne disease that occurs in tropical and subtropical areas of the world. Mild dengue fever causes a high fever, rash, and muscle and joint pain. A severe form of dengue fever, also called dengue hemorrhagic fever, can cause severe bleeding, a sudden drop in blood pressure (shock) and death.Millions of cases of dengue infection occur worldwide each year. Dengue fever is most common in Southeast Asia and the western Pacific islands, but the disease has bee...
Many people, especially children and teens, may experience no signs or symptoms during a mild case of dengue fever. When symptoms do occur, they usually begin four to seven days after you are bitten by an infected mosquito.Dengue fever causes a high fever — 104 F degrees — and at least two of the following symptoms: 1. Headache 2. Muscle, bone and joint pain 3. Nausea 4. Vomiting 5. Pain behind the eyes 6. Swollen glands 7. RashMost people recover within a week or so. In some cases, symptoms...
Dengue fever is caused by any one of four types of dengue viruses spread by mosquitoes that thrive in and near human lodgings. When a mosquito bites a person infected with a dengue virus, the virus enters the mosquito. When the infected mosquito then bites another person, the virus enters that person's bloodstream.After you've recovered from dengue fever, you have immunity to the type of virus that infected you — but not to the other three dengue fever virus types. The risk of developing seve...
Factors that put you at greater risk of developing dengue fever or a more severe form of the disease include: 1. Living or traveling in tropical areas. Being in tropical and subtropical areas increases your risk of exposure to the virus that causes dengue fever. Especially high-risk areas are Southeast Asia, the western Pacific islands, Latin America and the Caribbean. 2. Prior infection with a dengue fever virus. Previous infection with a dengue fever virus increases your risk of having seve...
If severe, dengue fever can damage the lungs, liver or heart. Blood pressure can drop to dangerous levels, causing shock and, in some cases, death.
One dengue fever vaccine, Dengvaxia, is currently approved for use in those ages 9 to 45 who live in areas with a high incidence of dengue fever. The vaccine is given in three doses over the course of 12 months. Dengvaxia prevents dengue infections slightly more than half the time.The vaccine is approved only for older children because younger vaccinated children appear to be at increased risk of severe dengue fever and hospitalization two years after receiving the vaccine.The World Health Or...
Large genetic differentiation and low variation in vector competence for dengue and yellow fever viruses of Aedes albopictus from Brazil, the United States, and the Cayman Islands. The American journal of tropical medicine and hygiene, 2003,69:105-114.
What is dengue? Dengue viruses are spread to people through the bite of an infected Aedes species (Ae. aegypti or Ae. albopictus) mosquito. Dengue is common in more than 100 countries around the world. Forty percent of the world’s population, about 3 billion people, live in areas with a risk of dengue.
A virus is a submicroscopic infectious agent that replicates only inside the living cells of an organism. Viruses infect all types of life forms, from animals and plants to microorganisms, including bacteria and archaea.